Church & Dwight Co., Inc. (CHD) gains on deep earnings beat
Church & Dwight Co., Inc. (CHD) gained after a deeper-than-headline earnings beat, with stronger organic growth, margin expansion, and raised guidance. The quarter showed volume-led momentum across key brands and segments, helping support the stock’s move despite its premium valuation.
Church & Dwight Co., Inc. (NYSE: CHD) delivered a solid earnings beat, with adjusted EPS of $0.92 and revenue of $1.60 billion topping estimates. The company also raised its full-year outlook after posting 5.1% organic sales growth and 170 basis points of gross margin expansion, signaling stronger demand and better profitability for investors.
Church & Dwight Co., Inc. (CHD) gains on Earnings Beat
Church & Dwight Co., Inc. (CHD) beat estimates in its latest quarter, with adjusted EPS of $0.92 versus $0.90 expected and revenue of $1.60B versus $1.58B. Shares gained 1.75% to $107.86 in regular trading, while volume reached 2,000,927 shares against an average of 1,870,675.
The CHD earnings report combined a beat with stronger organic growth, margin expansion, and higher full-year guidance. That mix matters for a consumer staples company trading near its recent high, because investors need more than steady demand to support a premium valuation.
Key Takeaways
Adjusted EPS reached $0.92, above the $0.90 estimate. Revenue came in at $1.60B, ahead of the $1.58B consensus.
Organic sales grew 5.1%, led by 4.6% volume growth and 0.5% positive price and mix. Gross margin expanded 170 basis points to 46.8%.
Consumer International was the strongest reported segment, with organic sales growth of 7.8%. Consumer Domestic grew 4.4%, while Specialty Products grew 5.0%.
CHD raised its 2026 outlook to roughly 0.5% net sales growth, 5% organic sales growth, and 7% adjusted EPS growth. Fourth-quarter guidance calls for about 4% organic growth and 17% to 19% adjusted EPS growth.
The operating story remains volume-led. Therabreath, ARM & HAMMER cat litter, and international brands helped drive the quarter, while management continues to emphasize innovation and distribution.
Analyst sentiment remains constructive. The current consensus is Buy, with 18 buy ratings, 15 holds, and one sell. Oppenheimer raised its price target to $120 from $115 and maintained an Outperform rating.
Financial Performance: Volume and Margins Carry the Quarter
CHD's $1.60B in revenue marked an improvement from $1.53B in the June quarter and $1.47B in the March quarter. The latest result also exceeded the $1.58B estimate, giving the company a clean top-line beat.
Adjusted EPS rose to $0.92 from $0.89 in the July 31 earnings print. The prior quarter came in slightly below its $0.896 estimate, so the latest result also shows a better earnings outcome after that narrow miss. The improvement came alongside stronger sales and wider gross margins.
The margin result deserves close attention. Gross margin reached 46.8%, an expansion of 170 basis points. At the same time, organic sales growth relied more on units than pricing. Volume contributed 4.6%, while price and mix added 0.5%. That balance gives the quarter more substance than a result driven mainly by price increases.
Segment results were broad. Consumer Domestic posted 4.4% organic growth, supported by household and personal care brands. Consumer International grew 7.8%, outpacing the domestic business and highlighting CHD's ability to scale acquired brands across regions. Specialty Products grew 5.0%, a solid result compared with the division's $299M revenue in 2025.
The brand portfolio supplied several clear growth engines. Therabreath continued to gain share in oral care, while ARM & HAMMER cat litter remained a strong contributor. Management also cited international expansion and new product distribution as key drivers. This is the company’s familiar playbook, but the latest numbers show that the playbook is still producing volume.
The guidance increase adds weight to the report. Full-year organic growth now stands near 5%, up from the previous 4% to 5% range cited in the updated commentary. Adjusted EPS growth is expected near 7%. For the fourth quarter, CHD expects about 4% organic growth and 17% to 19% adjusted EPS growth. Those figures set a higher bar for the holiday quarter, but they also show management entering the back half with confidence.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CHD rose 2.83% in premarket trading after the earnings announcement. By 3:30 p.m. ET on Oct. 30, the stock traded at $107.86, up 1.75%. Trading volume was above its average, which shows that the move attracted more participation than a routine defensive-stock session.
The immediate reaction fits the numbers: EPS beat estimates, revenue beat estimates, organic growth exceeded the prior 3% outlook, and gross margin expanded. In consumer staples, that combination can matter more than a single-quarter revenue surprise because it addresses both demand and profitability.
Oppenheimer raised its CHD price target to $120 from $115 on Oct. 28 and kept an Outperform rating. Other recent target changes were more mixed. Barclays cut its target to $83 from $86 while keeping an Underweight rating. Wells Fargo reduced its target to $105 from $110 but retained Overweight.
Several firms also raised targets earlier in the year. UBS moved to $107 from $104, Citigroup raised its target to $105 from $100, TD Cowen lifted its target to $97 from $95, and RBC Capital increased its target to $115 from $114. The pattern shows a constructive but divided view. Analysts recognize CHD's brand strength, yet valuation remains part of the debate.
Before the report, CHD traded near $108.93, its cited 52-week high, at roughly 33 times trailing earnings and 28 times forward earnings. The stock's gains after the beat show that the market rewarded execution, but the valuation leaves less room for an operating stumble.
Management Commentary: Innovation Remains the Growth Engine
CEO Richard Dierker has framed CHD's strategy around resilient categories, value-focused products, innovation, and distribution. His broader macro view from the Q2 CHD earnings call remains relevant to the latest results: consumer demand has held up while the company has gained share.
“Conditions remain dynamic. However, our categories are growing ahead of our original expectations, and Church & Dwight is growing even faster.” - Richard Dierker, CEO, Earnings Call
Dierker has also pointed to low household penetration in several brands. That creates a practical route for growth through broader distribution rather than relying only on higher prices. Therabreath, Hero, and Miss Mouth’s each operate below their category penetration levels, giving CHD a clear expansion framework.
CFO Lee McChesney has focused on the financial effect of that strategy. The latest guidance places adjusted EPS growth near 7%, while fourth-quarter EPS growth is expected at 17% to 19%. His earlier comments also stressed the link between sales, acquisitions, and earnings.
“Strong organic growth and the contributions from our acquisitions more than offset the impact of our 2025 business exits and led to reported net sales growth of a positive 1.6% in the quarter, ahead of our expectations.” - Lee McChesney, CFO, Earnings Call
In plain English, CHD is using better volume and margin performance to fund brand investment. That can suppress near-term operating leverage, but it supports the distribution and innovation spending needed to keep the growth rate from fading.
Analyst Q&A Highlights
The Q&A pressed management on the source of organic growth. Rupesh Parikh of Oppenheimer asked which areas drove the upside. The question tested whether the beat came from one temporary product win or from a wider portfolio trend.
“At a high level, what are some of the areas that drove the significant upside that we saw on that line item?” - Rupesh Parikh, Oppenheimer
“The good news is it was pretty broad-based. But as we said in the release, I think Therabreath, cat litter, I would say ARM & HAMMER laundry was kind of flattish.” - Richard Dierker, CEO, Earnings Call
Dierker's answer defended the breadth of the portfolio while conceding that ARM & HAMMER laundry did not lead the quarter. McChesney added that home care and personal care performed well across Europe, Asia, and Latin America. The response supports the current segment data, especially the 7.8% international growth.
Parikh also pushed for more detail on Miss Mouth’s, the stain remover acquisition completed in June. Management gave a positive strategic answer but stopped short of a multi-year growth rate.
“As we look out the next couple of years, is there any more granularity you can give in terms of the types of growth rates you expect for the business?” - Rupesh Parikh, Oppenheimer
“I think it's a little early to do that. I don't think we've been more excited about an acquisition in a long time.” - Richard Dierker, CEO, Earnings Call
Management did provide concrete operating evidence. Miss Mouth’s reached a 13% share at one major retailer after only a few months, while household penetration stood near 3% against 50% for the category. The opportunity is therefore tied to distribution and penetration, not just an optimistic acquisition narrative.
Bottom Line
This CHD earnings report delivered the right combination: an EPS and revenue beat, volume-led organic growth, wider margins, and higher guidance. The stock's valuation remains demanding, but the 5% organic growth outlook and strong international performance give the investment case operating support.
For investors, the central test is execution. CHD has raised the bar for the fourth quarter, and its ability to convert brand innovation and distribution gains into sustained volume will determine whether the recent gains can become a longer-term trend.
+Did Church & Dwight (CHD) beat earnings estimates this quarter?
Yes. Church & Dwight reported adjusted EPS of $0.92 versus the $0.90 consensus estimate, and revenue of $1.60 billion versus $1.58 billion expected.
+Why did CHD stock rise after earnings?
Shares rose because the company beat on both earnings and revenue, posted 5.1% organic sales growth, and expanded gross margin by 170 basis points to 46.8%. Investors also reacted positively to higher full-year guidance.
+What was Church & Dwight's organic sales growth in the latest quarter?
Organic sales grew 5.1% in the quarter. Growth was driven mainly by 4.6% volume growth, with price and mix contributing 0.5%.
+Did Church & Dwight raise its guidance for 2026?
Yes. Church & Dwight raised its 2026 outlook to about 0.5% net sales growth, 5% organic sales growth, and 7% adjusted EPS growth. For the fourth quarter, it guided to about 4% organic growth and 17% to 19% adjusted EPS growth.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on CHD?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
